29 Jun 2017 11:21
Tiziana Life Sciences plc
("Tiziana" or "the Company")
Results of Annual General Meeting
At the Annual General Meeting of the Company held at 10.30 a.m. on Thursday 29 June 2017 all the resolutions proposed were duly passed.
Details of the proxy voting at the Annual General Meeting will be posted to the Company's website later today.
For more information go to http://www.tizianalifesciences.com
Contact:
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder
| +44 (0)20 7493 2853 |
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner
| +44 (0)20 7213 0880 |
Beaufort Securities Limited (Broker) Saif Janjua
| +44 (0)20 7382 8300 |
FTI Consulting Simon Conway / Natalie Garland-Collins | +44 (0)20 3727 1000 |
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.